CA-125 levels after surgical exploration and radioactive chromic phosphate in ovarian cancer patients

Sharmila K. Makhija, W. J. Spanos, T. G. Day, D. Doering

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Trends in CA-125 levels after completion of therapy in ovarian cancer patients who received intraperitoneal radioactive chromic phosphate therapy (32P) after primary surgical resection or second-look surgery were evaluated. Ninety patients who underwent surgical exploration and 32P were reviewed. Twenty-nine patients were excluded due to insufficient number of CA-125 levels or recurrence within 12 months, with 61 patients with serial CA-125 levels and no evidence of disease for 12 months available for analysis. 32P followed initial resection in 24 patients (16 Stage I, 3 Stage II, 5 Stage III). 32P followed chemotherapy and second-look procedures in 37 patients (4 Stage I, 3 Stage II, 27 Stage III, 3 Stage IV). Elevated CA-125 levels were present in 25 (41%) patients within 12 months of 32P (46% after primary exploration, 38% after second-look). The degree of CA-125 elevation (U/ml) was 30-100 (23%), 100-200 (11%), and >200 (7%). Of the 25 patients with an elevated CA-125, the elevation persisted more than 4 months in 11 (44%). All but two patients had normal CA-125 levels by 12 months. An abnormal elevation in CA-125 was seen in 33% of patients 4 months after receiving 32P and abdominal surgery, with values ranging as high as 500 U/ml. Although elevations in CA-125 are reported following surgery alone, the duration of elevation appears to be longer with 32P. Therefore, persistent elevations of CA-125 following 32P between 4 and 12 months should be judged with caution as they may not reflect recurrent disease.

Original languageEnglish (US)
Pages (from-to)85-88
Number of pages4
JournalGynecologic Oncology
Volume63
Issue number1
DOIs
StatePublished - Oct 1996
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Second-Look Surgery
chromic phosphate
Recurrence
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

CA-125 levels after surgical exploration and radioactive chromic phosphate in ovarian cancer patients. / Makhija, Sharmila K.; Spanos, W. J.; Day, T. G.; Doering, D.

In: Gynecologic Oncology, Vol. 63, No. 1, 10.1996, p. 85-88.

Research output: Contribution to journalArticle

@article{eb446e406aac4320b3d910e6aca3e285,
title = "CA-125 levels after surgical exploration and radioactive chromic phosphate in ovarian cancer patients",
abstract = "Trends in CA-125 levels after completion of therapy in ovarian cancer patients who received intraperitoneal radioactive chromic phosphate therapy (32P) after primary surgical resection or second-look surgery were evaluated. Ninety patients who underwent surgical exploration and 32P were reviewed. Twenty-nine patients were excluded due to insufficient number of CA-125 levels or recurrence within 12 months, with 61 patients with serial CA-125 levels and no evidence of disease for 12 months available for analysis. 32P followed initial resection in 24 patients (16 Stage I, 3 Stage II, 5 Stage III). 32P followed chemotherapy and second-look procedures in 37 patients (4 Stage I, 3 Stage II, 27 Stage III, 3 Stage IV). Elevated CA-125 levels were present in 25 (41{\%}) patients within 12 months of 32P (46{\%} after primary exploration, 38{\%} after second-look). The degree of CA-125 elevation (U/ml) was 30-100 (23{\%}), 100-200 (11{\%}), and >200 (7{\%}). Of the 25 patients with an elevated CA-125, the elevation persisted more than 4 months in 11 (44{\%}). All but two patients had normal CA-125 levels by 12 months. An abnormal elevation in CA-125 was seen in 33{\%} of patients 4 months after receiving 32P and abdominal surgery, with values ranging as high as 500 U/ml. Although elevations in CA-125 are reported following surgery alone, the duration of elevation appears to be longer with 32P. Therefore, persistent elevations of CA-125 following 32P between 4 and 12 months should be judged with caution as they may not reflect recurrent disease.",
author = "Makhija, {Sharmila K.} and Spanos, {W. J.} and Day, {T. G.} and D. Doering",
year = "1996",
month = "10",
doi = "10.1006/gyno.1996.0283",
language = "English (US)",
volume = "63",
pages = "85--88",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - CA-125 levels after surgical exploration and radioactive chromic phosphate in ovarian cancer patients

AU - Makhija, Sharmila K.

AU - Spanos, W. J.

AU - Day, T. G.

AU - Doering, D.

PY - 1996/10

Y1 - 1996/10

N2 - Trends in CA-125 levels after completion of therapy in ovarian cancer patients who received intraperitoneal radioactive chromic phosphate therapy (32P) after primary surgical resection or second-look surgery were evaluated. Ninety patients who underwent surgical exploration and 32P were reviewed. Twenty-nine patients were excluded due to insufficient number of CA-125 levels or recurrence within 12 months, with 61 patients with serial CA-125 levels and no evidence of disease for 12 months available for analysis. 32P followed initial resection in 24 patients (16 Stage I, 3 Stage II, 5 Stage III). 32P followed chemotherapy and second-look procedures in 37 patients (4 Stage I, 3 Stage II, 27 Stage III, 3 Stage IV). Elevated CA-125 levels were present in 25 (41%) patients within 12 months of 32P (46% after primary exploration, 38% after second-look). The degree of CA-125 elevation (U/ml) was 30-100 (23%), 100-200 (11%), and >200 (7%). Of the 25 patients with an elevated CA-125, the elevation persisted more than 4 months in 11 (44%). All but two patients had normal CA-125 levels by 12 months. An abnormal elevation in CA-125 was seen in 33% of patients 4 months after receiving 32P and abdominal surgery, with values ranging as high as 500 U/ml. Although elevations in CA-125 are reported following surgery alone, the duration of elevation appears to be longer with 32P. Therefore, persistent elevations of CA-125 following 32P between 4 and 12 months should be judged with caution as they may not reflect recurrent disease.

AB - Trends in CA-125 levels after completion of therapy in ovarian cancer patients who received intraperitoneal radioactive chromic phosphate therapy (32P) after primary surgical resection or second-look surgery were evaluated. Ninety patients who underwent surgical exploration and 32P were reviewed. Twenty-nine patients were excluded due to insufficient number of CA-125 levels or recurrence within 12 months, with 61 patients with serial CA-125 levels and no evidence of disease for 12 months available for analysis. 32P followed initial resection in 24 patients (16 Stage I, 3 Stage II, 5 Stage III). 32P followed chemotherapy and second-look procedures in 37 patients (4 Stage I, 3 Stage II, 27 Stage III, 3 Stage IV). Elevated CA-125 levels were present in 25 (41%) patients within 12 months of 32P (46% after primary exploration, 38% after second-look). The degree of CA-125 elevation (U/ml) was 30-100 (23%), 100-200 (11%), and >200 (7%). Of the 25 patients with an elevated CA-125, the elevation persisted more than 4 months in 11 (44%). All but two patients had normal CA-125 levels by 12 months. An abnormal elevation in CA-125 was seen in 33% of patients 4 months after receiving 32P and abdominal surgery, with values ranging as high as 500 U/ml. Although elevations in CA-125 are reported following surgery alone, the duration of elevation appears to be longer with 32P. Therefore, persistent elevations of CA-125 following 32P between 4 and 12 months should be judged with caution as they may not reflect recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=0030271929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030271929&partnerID=8YFLogxK

U2 - 10.1006/gyno.1996.0283

DO - 10.1006/gyno.1996.0283

M3 - Article

C2 - 8898174

AN - SCOPUS:0030271929

VL - 63

SP - 85

EP - 88

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -